As of June 30, 2026, the Company’s subsidiaries are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Percentage |
|
|
|
|
|
|
|
|
of direct |
|
|
|
|
|
|
|
|
or indirect |
|
|
|
|
|
|
Date of |
|
ownership |
|
|
|
|
Place of |
|
incorporation or |
|
by the |
|
|
Subsidiaries |
|
incorporation |
|
acquisition |
|
Company |
|
Principal activities |
I-Mab Biopharma US Ltd. |
|
United States |
|
February 28, 2018 |
|
100% |
|
Research and development of innovative medicines |
I-Mab Biopharma Hong Kong Limited (“I-Mab Hong Kong”) |
|
Hong Kong |
|
July 8, 2016 |
|
100% |
|
Investment holding |
I-Mab Bio-tech (Tianjin) Co., Ltd. (“I-Mab Tianjin”) |
|
People’s Republic of China |
|
July 15, 2017 |
|
100% |
|
Research and development of innovative medicines |
Visara, Inc. |
|
United States |
|
September 24, 2025 |
|
58% |
|
Research and development of innovative ophthalmology medicines |
Bridge Health Bio-Tech (Shanghai) Co., Ltd. (“Bridge Health”) |
|
People’s Republic of China |
|
October 28, 2025 |
|
100% |
|
Intellectual property holding |
NovaBridge Biosciences (Shanghai) Co. Ltd. |
|
People’s Republic of China |
|
March 2, 2026 |
|
100% |
|
Peoples Republic of China ("PRC") operations |
NovaBridge Oncology |
|
Cayman Islands |
|
March 12, 2026 |
|
100% |
|
Investment holding |
NovaBridge Oncology (BVI) Limited |
|
British Virgin Islands |
|
March 24, 2026 |
|
100% |
|
Investment holding |
NovaBridge CV Limited |
|
Cayman Islands |
|
March 26, 2026 |
|
100% |
|
Investment holding |
OncoArc GmbH |
|
Switzerland |
|
June 9, 2026 |
|
100% |
|
Research and development of innovative oncology medicines |
|